NCT00385190
Completed
Phase 1
An Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of Study Drug Administred Orally to Healthy Japanese Male Subjects
Wyeth is now a wholly owned subsidiary of Pfizer0 sites24 target enrollmentJuly 2006
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Healthy
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Enrollment
- 24
- Primary Endpoint
- Safety and pharmacokinetics
- Status
- Completed
- Last Updated
- 16 years ago
Overview
Brief Summary
The purpose of the study is to assess the safety and tolerability of ascending multiple oral doses of HCV-796 in healthy Japanese male subjects.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead ECG.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Safety and pharmacokinetics
Similar Trials
Completed
Phase 1
Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male SubjectsSchizophreniaNCT00505973Wyeth is now a wholly owned subsidiary of Pfizer24
Completed
Phase 1
Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female SubjectsSchizophreniaNCT00458107Wyeth is now a wholly owned subsidiary of Pfizer64
Completed
Phase 1
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With SchizophreniaSchizophreniaNCT02720263Astellas Pharma Global Development, Inc.48
Completed
Phase 1
Study Evaluating Multiple Oral Doses of PPM-204 in Healthy Japanese Male SubjectsDiabetes MellitusNCT00448032Wyeth is now a wholly owned subsidiary of Pfizer
Completed
Phase 1
Multiple Rising Oral Dose Study of PG 760564 Administered Twice Daily to Healthy Male/Female Volunteers for 14 DaysHealthyNCT00791388Procter and Gamble45